Abstract:
OBJECTIVE: To describe the clinical characteristics and
evolution of our series of medication-related osteonecrosis
of the jaws (MRONJ) associated with denosumab in
osteoporotic patients.
MATERIAL AND METHODS: We present 10 new cases
of MRONJ in patients receiving denosumab for osteoporosis.
We describe the mean doses of denosumab,
previous bisphosphonate intake, and the clinical characteristics
associated with the osteonecrosis, such as local
contributing factors, symptoms, and evolution after
treatment.
RESULTS: The mean number of denosumab doses was
3.4 2.2. In 90% of patients, there was a prior history of
oral bisphosphonate intake, with a mean duration of
46.78 25.11 months. The most common local factor
was dental extraction (6 cases; 60%), and most cases
had necrotic bone exposure (9/10, 90%). Sclerosis of the
bone was the most common radiographic finding. Stage
1 was the most common ONM stage, found in 80%.
‘Cure’ after conservative treatments was obtained in
71.4%.
CONCLUSIONS: Most of our cases were in the early
stages of MRONJ, and the success rate after conservative
treatment was high.